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The general introduction provides an overview of present knowledge regarding
hemoglobinopathies and thalassemias, with special attention to sickle cell disease
(SCD), o-thalassemia and the screening and diagnosis of these disorders. The
hemoglobin (Hb) disorders are a group of autosomal recessive diseases
characterized by either the synthesis of a structurally abnormal globin chain or
reduced synthesis of one or more normal globin chains. Both Hb structural and
synthesis variants may interfere with Hb function, erythrocyte survival and blood
flow (rheology) and thereby cause a variety of diseases collectively referred to as
hemoglobinopathies and thalassemias. The quantitatively most important
structural Ffb variants encountered in the Curaqao population are sickle cell HbS
(B6Glu-+Val;5.03% heterozygotes) and HbC (B6Glu-+Lys; 6.70oÁ heterozygotes),
while a-thalassemia-2 (22.7% heterozygotes) is the major Hb synthesis variant.
SCD (i.e. HbSt HbSC, HbSB-thalassemia) is a heterogenic disease that is
characterized by hemolytic and vasoocclusive components. The vasoocclusive
component adds most to morbidity and mortality. The pathophysiological
cascade leading from the mutation to its clinical presentation is as yet unclear.
HbS is poorly soluble at low oxygen tension and solutions with deoxy HbS above
120 g/L are fully in the gel-state. The gel-state changes red blood cell (RBC) shape
from biconcave into that of the typical sickled RBC that tends to occlude the
microcirculation. The present notion is that the cascade is initiated by a
combination of genetic and environmental factors that ultimately cause a pro-
inflammatory, pro-adhesive and hypercoagulable phenotype. SCD should be
considered as an endothelial disease in which interaction between the hemolytic
component and the abnormal theological properties of sickle RBC gives rise to
chronic endothelial activatiory chronic damage to virtually all organs and
occasional precipitation to painÍul vasoocclusive crisis. Crisis precipitating factors
include inÍectiory dehydration, cold, low-oxygen tension, acidosis and others. The
heterogeneity of the disease is largely explained by a number of disease-
ameliorating or aggravating genetic and environmental factors. Disease severity
is related to Hb concentratiory propensity of RBC to adhere to vascular
endothelium, co-existing cr- or B-thalassemia, trans (e.g. HbC) and cis acting B-
structural variants, hereditary persistence of HbF (HPFH), haplotype, social class
and psychosocial factors. Nitric oxide (NO) has recently been shown to play a
central role in SCD vascular homeostasis, by maintaining basal and stimulated
vasomotor tone, limiting platelet aggregation and ischemia-reperfusion injury,
modulating endothelial proliferation, reducing VCAM-1 gene transcription and
HbF reinduction. Low plasma arginine (the precursor of NO) and NO-metabolites
during vasoocclusive crisis suggests that arginine might be a limiting factor in
life-threatening situations in which NO-availability might be of crucial
importance. SCD requires specialized comprehensive care to achieve optimal
outcome in the sense of morbidity and mortality. Genetic counseling and family
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education includes the education of its autosomal recessive inheritance and the
provision of accurate inÍormation about genetic risk, clinical course, medical
complications and treatment. A number of therapies have been proposed and
developed. Stem-cell transplantation and chronic transfusion can cure SCD or
dramatically lessen its severity. Other, mostly experimental, treatment modalities
include red cell rehydration, antiadhesion therapy, antioxidant therapy,
antithrombotic therapy, antisickling therapy and HbF reinduction (notably
through hydroxyurea). Gene therapy offers promise, but progïess has been slow.
Modulation of environmental influences by institution of supportive measures is
feasible for all. Avoidance of crisis precipitating factors for the prevention of acute
effects and maintenance of a healthy endothelium for the prevention of both acute
and long-term effects are ensuing consequences of the current pathophysiological
concept. A healthy endothelium benefits from good nutrition, including sufficient
calories, folate, zinc,low iron, antioxidants, fish oil and possibly arginine
Mutations that result in impairment or complete abolition of cr-chain (cr-thalasse-
mia) or p-chain (p-thalassemia) production are the most commonly encountered
causes of the thalassemia syndromes. The two major types oÍ o-thalassemia
derive from loss of 1 to 4 a-genes. They are denoted as type L (heterozygous:
aa/--, and homozygous: :/-) and type 2 (heterozygous: oo/cr - and homozy-
gous: -c/-o). The double heterozygous mixture of cr-thalassemia types L and 2 is
denoted as -uf --. cr-Thalassemias have high incidences in Mediterraneans and
South-East Asians (o-thalassemia-1 and 2), and blacks and Arabs (cr-thalassemia-
2). Hematologic parameters of subjects with heterozygous cr,-thalassemia-2 (aa/-
c) are frequently within normal limits. Homozygous q-thalassemia-2 (-cr/-a) and
heterozygous cr-thalassernia-L (ua/:) lead to hypochromia, microcytosis and
accumulation of unpaired Hb chains. Usually these conditions do not require
clinical attention, but loss of 3 (HbH disease) or 4 cr-genes causes moderately
seveïe hemolytic anemia and death (hydrops fetalis), respectively.
The diagnosis and screening of hemoglobinopathies and thalassemias may either
be based on phenotypic- or molecular diagnostic testing. The present cornerstone
is Hb-profiling by high performance liquid chromatography (HPLC). Preventive
measures in Curaqao through genetic counseling and early diagnosis after birth
may be accomplished by screening of all newborns for HbSS, HbSC and HbSB-
thalassemia. From an index patient, investigations may be extended to family
members, notably for sake of genetic counseling. With respect to adults, it may
especially be worth while to screen all pregnant women for hemoglobinopathies.
Distinction between cr-thalassemia and iron deficiency is important for the need
to treat iron deficiency, but not for the establishment of the widely occurdng cr-
thalassemia-2. Proper distinction may prevent treatment of cr-thalassemia with
iron supplements. Additional measurement of the soluble transferrin receptor
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(sTfR) concentration and the sTfR/ferritin ratio may be useful for distinction
between iron deficiency and anemia of chronic disease
In chapter II.L. we evaluated the use of an HPLC method for screening
hemoglobins in cord blood. Genotype frequencies of HbS and HbC and cr- and B-
thalassemia were established in babies born in CuraEao. During three months,
67.2% of all (7a8) newborns were screened:122 (24.3%) had abnormal Hb pattern:
53 (43.4%) had a hemoglobinopathy (HbS or HbC), 64 (52.2%) cr-thalassemia
(HbBart's>0.5%, heterozygous or homozygous cr-thalassemia-2), and 5 (4,1%) a
hemoglobinopathy plus cr,-thalassemia. None of the newborns with heterozygous
HbS and HbC had concomitant p*-thalassemia. The population genotype
frequency of heterozygous cr,-thalassemia-2 was calculated to be 30.7%. Based on
the HPLC results, we estimate that 67.1% of newborns with heterozygous a-
thalassemia-2 remain undetected. A coincidental Íinding was a relation between
demonstrable alpha-thalassemia and short gestation. The HPLC method was
preeminently suitable for screening cord-blood samples.
Cord blood hemoglobin Barts (HbBarts) and hemocytometric indices may be used
for classification of newborns into those without o-thalassemia-2 (crcr/ocr) and
with heterozygous o-thalassemia-2 (-utz / gLcr). In chapter II.2 we investigated by
logistic regression analysis whether the combination of HbBarts and
hemocytometric indices improves classification compared with classification
based on a single analyte. HbBarts percentages and hemocytometric indices were
determined in cord blood of 208 consecutive newborns in Curaqao (Netherlands
Antilles). Of these, 157 l":.ad aaf uu and 51 nuO -osz f aa, as established by DNA
analysis. Between-group differences were significant for erythrocytes, mean cell
volume, mean cell hemoglobin (MCH), mean cell hemoglobin concentration,
platelets, HbFo, and HbBarts. The Logit equation of the logistic regression model,
using MCH (pg) and FfbBarts (%), was: 42.7L64 + 5.7916(HbBarts) - 1.3110(MCH).
A sensitivity oÍ 100% was reached at a Logit value of -3.70. The corresponding
specificity was 62.2%, and the predictive value of a positive test (PV.) was 46.3%
(95% conÍidence inteïval, 37.0-55.7%). The relative inÍormation gains were as
follows: 88% for the HbBarts-MCH combination,26% for MCH (not significant),
and 0% for HbBarts compared with the 24.6% -u37/ oo, prevalence. We conclude
that the combined use of cord blood FlbBarts and MCH improves classification
compared with classification based on single hemocytometric indices.
In chapter II.3 we investigated whether the previously established higher
prematurity frequency of newborns with 0.5%<HbBarts32.0% and HbBarts>2.0%,
compared with FlbBarts<0.5%, is associated with genotypically demonstrable by
a,-thalassemia-2. Cord blood was collected from2l'1. consecutive spontaneous life
births in Curagao (The Netherlands Antilles). HbBarts percentages and a-
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thalassemia-2 genotypes (i.e. aa/aa, -uf ua and -a/-o-) were established and
related to their prematurity (<37 weeks) frequencies and gestation lengths.
Newborns with 0.5%<HbBarts<2.0% (n= 30; odds ratio Íor prematurity:1.34 (1.34-
18.58); mean gestational age 38.3 weeks) and HbBarts>2.O% (n=6; odds ratio: 41.50
(a.79-a87.8);33.5 weeks) had higher prematurity frequencies and shorter gestation
lengths, compared with newborns with HbBarts<0.S% (n=174; 39.3 weeks).
Newborns with -crr/crcr (n= 51; odds ratio for prematurity: 3.55 (1.16-10.73); mean
gestational age 39.5 weeks) had higher prematurity frequencies compared with
newborns with ao/ocr (n= 158; 39.0 weeks). From the 18 prematures 10 had
HbBarts>O.S% and t had -af uo.,. Classification into aaf olc',, -af au and -af -a
coincided to a large extent with classification into HbBarts<0.5%,
0.5%<HbBarts<2.0% and H.bBafts>LO%, respectively. Misclassification was
partially due to the gestational age dependency of HbBarts. We conclude that
newborns with heterozygous cr-thalassemia-2 have higher prematurity frequency
than their unafÍected counterparts.
In chapter III.1 we determined glycohemoglobin (gly-Hb) reference ranges of
non-diabetic adults with HbAA (n = 1\, HbAS (n = 37), HbAC (n = 22\, HbSC (n
= 8), F{bSS (" = 6) and HbCC (" = 3) by 13 methods, based on affinity
chromatography, HPLC, electrophoresis and immunoassay. Gly-Hb of subjects
with HbAS and HbAC can be measured without major difficulties by most
methods. Some give rise to absolute gly-Hb difÍerences 21,% compared with
subjects with HbAA. Measurement of HbAr"/total Hb cannot be recommended.
Some HPLC and immunoassay methods cannot measure gly-Hb in subjects with
HbSC, HbSS and HbCC, whereas others may suÍfer from interference. Most
methods showed low gly-Hb, reflecting increased erythrocyte turnover. Use of
special reference ranges requires previous knowledge of the condition (affinity
chromatography and immunoassay) or separation oÍ gly-Hb and its precursor Hb
(HPLC and electrophoresis). Interpretation is, however, not recommended
because of the numerous factors that determine erythrocyte turnover.
Chapter III.2 reports on a study of parameters of calcium homeostasis and
vitamin D status in HbSS patients (median age 8 years, range 3-19;8 Íemales, 1,0
males) and matched HbAA controls living in the tropical island of Curaqao.
Serum calcium concentration in HbSS patients (2.32(0.07) mmol/L) was lower
(ANCOVA' P = 0.002) than that of HbAA controls (2.44(0.1-4)). None of the
subjects had hypocalcemia. There were no diÍÍerences in serum concentrations of
phosphate, total protein, albumiry intact parathyroid hormone (PTH), 25-
hydroxyvitamin D (87(27) nmol/L in patients, 86(15) nmol/L in controls) and
l,2S-dihydroxyvitamin D. There were no significant relations between PTH and
25(OH)D. We conclude that vitamin D status of HbSS patients in Curacao is
adequate.
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In chapter III.3 we emphasize the limitations of painÍul crisis frequency as a
parameter of disease severity. We also discuss the potential of immunological,
hematological and biochemical factors to serve as parameters of disease severity.
Vasoocclusion leads to pain, chronic organ damage, and a decreased lÍe
expectancy in patients with sickle cell disease. Therapeutic options for sickle cell
disease have usually been evaluated according to their capacity for reducing the
frequency of vasoocclusive crises requiring clinical attention. However, the
frequency of vasoocclusive crises is not representative for the rate of
accumulating organ damage in most sickle cell patients. This implies that the
frequency of vasoocclusive crises needn't correlate with disease severity and,
although being of importance, cannot solely serve as a parameter of treatment
efficacy. Therefore, additional new objective parameters are needed to effectively
study the vasoocclusive process in sickle cell disease. Several studies show that
intricate adhesive interactions between (red) blood cells, plasma components, and
endothelium play a crucial role in the pathophysiology of sickle cell
vasoocclusion, offering new potential parameters to effectively assess disease
severity as well as new therapeutical targets in the near future. Whether these
adhesive mechanisms involve the causes or the effects oÍ vasoocclusion will be
determined if their inhibitioru by interventive measures, results in therapeutic
benefits.
In chapter IV.l we investigated whether pediatric patients with sickle cell disease
(SCD) (914 years;27 homozygous SCD (HbSS); L9 sickle-C disease (HbSC)) have
different folate status compared with age-, sex-, and race-matched normal
hemoglobin (HbAA) controls (n = 20), and whether their folate status can be
improved by folate supplementation. The patients were supplemented with
vitamins Bo and 812 during one week and with folate during the following week.
Circulating folate, homocysteine, vitamin Bo and vitamin Brz levels were
measured at baseline (patients and controls), after one week and after two weeks
(patients). The patients had similar folate, vitamin Bo, and vitamin Bwbut higher
homocysteine levels compared with HbAA controls (12.7!4.5 vs. l-0.9+3.5 pmol/l;
P = 0.04). Vitamin Be and 812 supplementation did not change their homocysteine
levels, but folate supplementation caused a 53% reduction (to 5.7t1.6). We
conclude that patients with SCD have adequate vitamin Bo and Brz status, but
suboptimal folate status, leading to elevated plasma homocysteine levels. They
may therefore benefit from folate supplementation to reduce their high risk for
endothelial damage.
In chapters IV.2, IV.3 and IV.4 we embarked into a discussion on the adequate
folate status of SCD patients as reported by Rodriguez and coworkers (chapter
IV.2), the value of RBC folate as a parameter for folate status assessment in SCD
patients (chapter IV.3) and the high number oÍ pediatric SCD patients with low
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RBC folate found by Kennedy and coworkers (chapter IV.4). Rodriguez and
coworkers in the USA concluded that folic acid supplements are not required in
most SCD patients. This conclusion was based on similar plasma homocysteine in
pediatric SCD patients and controls, and differs from our observation in Curagao,
as described in chapter IV.1. The disparity might result from the fortiÍication of
many food products with folic acid in the USA. Interestingly at least 10% of their
patients exhibited plasma homocysteine levels above 9.4 prnol/\. This level is
consistent with the upper limit of homocysteine after Íolate supplementation in
our study and suggests that at least part of their patients might still benefit from
folic acid supplementation. In chapter IV.3 we report on the coincidental finding
that RBC folate is not to be taken as an adequate reflection of folate status in SCD
patients. RBC folate is largely established during erythropoiesis and subsequently
declines during RBC circulation. SCD patient therefore have higher RBC folate at
a given folate status, since their RBC have much shorter half-life compared with
unaffected controls. Use of special reference ranges for RBC folate for SCD
patients does not seem to be a genuine solution because of the many (genetic and
environmental) factors that inÍluence their RBC half-life. Plasma homocysteine
might be a better parameter for SCD Íolate status, although it should be kept in
mind that homocysteine is not merely dependent on folate status. In the light of
the inadequacy of RBC folate to establish folate status in SCD we conclude
(chapter IV.4) that the finding oÍ15% SCD patients with below-normal RBC folate
levels by Kennedy in the USA might be a conservative estimate. Since SCD
patients should exhibit higher RBC Íolate to have a folate status comparable with
controls, it might be expected that many of their SCD patients with normal RBC
folate actually have low-folate status. That these high numbers occuï despite the
prescription of 1 mg folic acid/day, should, in our opinion, not be regarded as an
indication for higher daily supplemental dosages. This notion derives from data
reported in chapter IV.5 in which we show that all SCD patients reach lowest
homocysteine levels from 700 pg folic acid daily.
Using homocysteine as a functional marker, we determined optimal folic acid,
vitamin 812, and vitamin 86 dosages in 21 pediatric sickle cell disease (SCD)
patients (11 HbSS, 10 HbSC; 7-\6 years). Chapter IV.S reports on the results of
this study. Daily supplements oÍ folic acid (400, 700, or L,000 pg), vitamin Bp (1.,3,
or 5 U.S. 1989 RDA), and vitamin Ba (1 or 3 U.S. 1989 RDA) were gradually
increased in an S2-week dose-escalation study. Blood was taken at 9 occasions for
measurements of erythrocyte (RBC) and serum folate, plasma vitamin Brz, whole-
blood vitamin Bo, and plasma homocysteine. Augmentation of folic acid from 700
to 1,000 pg and vitamin Brz from 3 to 5 RDA did not further decrease
homocysteine. Percentages of patients exhibiting significant individual
homocysteine decreases amounted to 43% (folic acid from 0 to 400 pLg, vitamins
Brz and Bo from 0 to 1, RDA) ,14% (folic acid from 400 to 700 pg),24% (vitaminBtz
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from 1 to 3 RDA), and 18% (vitamin Be from 1 to 3 RDA ). The lowest plasma
homocysteine at 82 weeks was 5.9 + / - 2.2 pmol/L. Patients with HbSS had higher
RBC Íolate than HbSC. The entire group exhibited an inverse relation between
RBC folate and hemoglobin. We conclude that RBC folate is less valuable for
folate status assessment in SCD patients. Optimal dosages are as follows: 700 p,g
folic acid (3.5-7 U.S. 1989 RDA), 3 U.S. 1989 RDA vitamin Bo (4.2-6.0 pg), and 3
U.S. 1989 RDA vitaminB6 (4.2-6.0 mg). A practical daily combination is 1 mg folic
acid (4.3-8.5 U.S. 1998 RDA when taken with meals), 6 pg vitamin Brz (2.5-5 U.S.
1998 RDA), and 6 mg vitamin Be (4.6-10 U.S. 1998 RDA). This combination may
by simple and relatively inexpensive means reduce these patients' inherently high
risk of endothelial damage.
Hyperhomocysteinemia is a modifiable risk factor for endothelial diseases. In
chapter IV.6 we review the current reports on plasma homoysteine levels in
patients with sickle cell disease (SCD). Several of these showed that these patients
have increased homocysteine. Folate, but also vitamin Brz and vitamin Bo, are
determinants of their homocysteine. We established optimal supplemental
dosages of these vitamins in 21 pediatric SCD patients by slowly increasing their
intakes in 82 weeks. These were estimated at: 700 ytg folic acid, 4.2-6.0 pg vitamin
Brz and 4.2-6.0 mg vitamin Bo. This combination is safe, relatively inexpensive and
might reduce their inherently high risk of endothelial damage caused by both the
hemolytic and vasoocclusive components of the disease.
Future perspectives
SCD is nowadays considered to be an endothelial disease that is characterized by
a pro-adhesive, pro-inÍlammatory and pro-coagulant phenotype. Any affordable
supportive measure that prevents this fragile 'steady state' from precipitation into
painÍul crisis and chest syndrome, is likely to contribute to reduced morbidity
and mortality. Most importantly, supportive measures are likely to limit silent
chronic obstruction, which probably contributes most to chronic organ damage
and its ultimately derived mortality. Supportive measures/ as opposed to
generally unaffordable and potentially risky or harmÍul therapies (e.9. bone
marrow transplants, chronic blood transfusions and hydroxyurea), are to be
found in family education (symptom recognition like splenic sequestration and
febrile disease, maintenance of hydratiory avoidance of adverse climatic
conditions), prophylactic immunization, prompt diagnosis and treatment oÍ
inÍectioru and last but not least good nutrition. The latter may especially aim at
the endothelium. A healthy endothelium benefits from sufficient calories, folate
(and vitamins Brz and B6), zinc, low iron, antioxidants (vitamins E and C; Se and
Zn), Íish oil and arginine.
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The higher RBC turnover in SCD requires higher intake of a variety of
micronutrients and possibly also macronutrients. Folate (preferably accompanied
by vitamins Brz and 86) reduces plasma homocysteine, which is a risk factor for
endothelial damage. Plasma homocysteine in SCD is e.g. associated with stroke.
In an open-label study design we (1) have established the optimal dosages of folic
acid, and vitamins Brz and Bo to reach the lowest homocysteine levels in patients
with SCD. Many SCD patients have marginal zinc status, which relates to poor
growth, delayed maturation and susceptibility to inÍection. In a previous study
(2) we found that zinc supplementation reduces the percentage irreversibly
sickled cells (ISC), but the percentage ISC has no established relation with
morbidity or mortality. Iron supplementation and repeated blood transfusions
are contraindicated, since they augment oxidative stress. A slightly hypochromic
anemia may be beneficial because oÍ the substantial delay in HbS polymerization
with only small decreases of the MCHC. Oxidative stress seems to be a common
end stage of many, if not all, pathophysiological pathways leading to cell damage
or death, but it is still questionable whether it can be controlled by augmentation
of antioxidant status. The latter is no simple concept, because it is determined by
a variety of synergistically acting antioxidants (e.g. vitamins E and C, carotenes,
flavonoids) involved in the limitation of the acute devastating effects of reactive
oxygen species, and also by many cofactors (e.g. Se, Zn) of enzymes involved in
their ultimate detoxification. In one of our previous studies (2) we found that fish
oil supplementation reduces serum triglycerides, which may notably be caused
by the expression of genes that govern intermediary metabolism (so called diet-
gene interaction). By then there were no available soft endpoints to investigate
whether the supplement also modulated the nowadays frequently used
parameters of endothelial activatioru inÍlammation or coagulation (3). In a small
recent study by others, fish oil has been shown to reduce the frequency of pain
episodes, possibly by reducing prothrombotic activity. Arginine supplementation
during crisis augmented nitric oxide (NO) metabolite formation by 78% and
seems to improve pulmonary hypertension. In a recent study (a) we found that
patients with steady state SCD in CuraEao have low plasma arginine and
concomitantly increased proline, which points at augmentation oÍ arginine flux
via the cytokine-activated pathway of arginase. Activation of this pathway limits
conversion of arginine to NO and thereby contributes to the low availability of
NO for vasodilation in SCD. It is our aim to investigate in the near future the
effect of supplementation of SCD patients with a combination of folic acid, zinc,
antioxidants (vitamins E and C), fish oil and arginine. The study design is based
on an open label trial that makes use of contemporary laboratory end points of
endothelial activation, inÍlammation and coagulation.
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